CWM
NTLA icon

CIBC World Markets’s Intellia Therapeutics NTLA Stock Holding History

CIBC World Markets’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$119K Sell
12,709
-9,808
-44% -$80.5K ﹤0.01% 1378
2025
Q1 		$160K Buy
+22,517
New +$227K ﹤0.01% 1523

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC World Markets's NTLA Position: Q2 2025 in Review

CIBC World Markets reduced its Intellia Therapeutics (NTLA) stake by 44% in Q2 2025, selling an estimated $80.5K and leaving 12,709 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

CIBC World Markets first reported a position in NTLA in Q1 2025 and has held it in 2 quarters since. The position peaked at $160K in Q1 2025. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • CIBC World Markets held 12,709 shares of Intellia Therapeutics worth $119K as of Q2 2025.
  • CIBC World Markets sold 9,808 Intellia Therapeutics shares in Q2 2025, an estimated $80.5K.
  • Intellia Therapeutics made up ﹤0.01% of CIBC World Markets's portfolio in Q2 2025, its #1378 holding.
  • CIBC World Markets first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • CIBC World Markets's Intellia Therapeutics position peaked at $160K in Q1 2025.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.